Title page

Prevalence use of nonsteroidal anti-inflammatory drugs in the general population with COVID-19 and associated COVID-19 risk, hospitalization, severity, death, and safety outcomes: A systematic review and meta-analysis

Running title: NSAIDs and COVID-19

Huilei Zhao^{1*}, B.D., Shanshan Huang^{2*}, M.D., Kaibo Mei^{3*}, M.D., Wen Shao², B.D.,
Jing Zhang⁴, M.D., Jianyong Ma⁵, M.D., Wengen Zhu⁶, M.D., Yuan Jiang^{7,8}, Ph.D.,
Peng Yu⁹, M.D., Xiao Liu^{7,8}, M.D.

1 Department of Anesthesiology, the Third Hospital of Nanchang, Jiangxi, 330006,
China

2 Medical college of Nanchang University, Jiangxi, 330006, China

3 Department of Anesthesiology, the Shangrao People's Hospital, Jiangxi, 330006,
China

4 Department of Anesthesiology, the Second Affiliated Hospital of Nanchang
University, Jiangxi, 330006, China

5 Department of Pharmacology and Systems Physiology University of Cincinnati
College of Medicine, Cincinnati, OH 45267

6 Department of Cardiology, the first affiliated Hospital of Sun Yat-sen University,
Guangzhou, 510080 China

7 Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen
University, Guangzhou, 510080 China

8 Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology,
Guangzhou, China

9 Department of Endocrine, the Second Affiliated Hospital of Nanchang University,
Jiangxi, 330006, China

*Dr. Zhao, Dr. Huang and Dr. Mei are co-first authors.

Corresponding author:

✉ Peng Yu, Email: upeng_jxndefy@163.com

✉ Xiao Liu, Email: liux587@mail.sysu.edu.cn

Abstract

Introduction: Recent reports of potential harmful effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with Corona Virus Disease 2019 (COVID-19) have provoked great concern. Therefore, the safety of NSAIDs is still questioned.

Methods: We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases from December 2019 to January 2021 to examine use prevalence for NSAIDs in general, as well as associated COVID-19 risk and outcomes. This study has been registered with PROSPERO (CRD42019132063)

Results: We included 25 studies with a total of 101,215 COVID-19 patients. The use of NSAIDs in COVID-19 patients reached 19%. Exposure to NSAIDs was not associated with significantly increased risk of developing COVID-19 (odds ratio [OR]=0.98, 95% confidence interval [CI]: 0.78-1.24; $I^2=82\%$), hospitalization (OR=1.06, 95%CI: 0.76-1.48; $I^2=81\%$), mechanical ventilation (OR=0.71, 95%CI: 0.47-1.06; $I^2=38\%$), and length of hospital stay. Moreover, use of NSAIDs was significantly associated with better outcomes, including severity of COVID-19 (OR=0.79, 95%CI: 0.71-0.89; $I^2=0\%$) and death (OR=0.68, 95%CI: 0.52-0.89; $I^2=85\%$) in patients with COVID-19. Regarding safety outcomes, exposure to NSAIDs was associated with increased risk of stroke (OR=2.32, 95%CI: 1.04-5.2; $I^2=0\%$), but not with myocardial infarction (OR=1.49; $p=0.66$; $I^2=0\%$), overt thrombosis (OR=0.76,

$p=0.50$; $I^2=28\%$) and major bleeding ($p=0.61$).

Conclusion: Based on current evidence, exposure to NSAIDs is not linked to increased odds or exacerbation of COVID-19 in the general COVID-19 population. Furthermore, administration of NSAIDs might have better outcomes and survival benefits in the general COVID-19 population, although potentially increasing the risk of stroke. Use of NSAIDs might be safe and beneficial in COVID-19. Future observational and randomized control trials are needed for further confirmation.

Keywords: nonsteroidal anti-inflammatory drugs, COVID-19, ibuprofen, aspirin, systematic review, meta-analysis

INTRODUCTION

Corona Virus Disease 2019 (COVID-19) is an acute respiratory disease caused by the novel virus called severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), which infects cells expressing the angiotensin-converting enzyme (ACE2) receptor and is currently prevalent worldwide[1, 2].

Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, celecoxib, and indomethacin are inexpensive and readily available drugs widely applied for their antiviral and anti-inflammatory characteristics[3]. Moreover, since most clinical symptoms of COVID-19 usually start from fever, a sign of pain, NSAIDs might be the most commonly used drugs in the general population. Therefore, NSAIDs provoke safety concerns in COVID-19. The concern was initially raised by several cases of COVID-19 reported by French researchers, with worsened symptoms after taking the NSAID ibuprofen[4]. Quite a few reports have revealed various side effects of NSAIDs and opposed their administration in COVID-19 patients[4-6]. Subsequently, the European Medicines Agency and the WHO claimed NSAIDs should not be precluded when clinically indicated, at least not all of NSAIDs, based on limited evidence in the covid-19 epidemic.

NSAIDs exert their effects by suppressing cyclooxygenase enzymes so that the synthesis of prostaglandins (PGs) is reduced. Substances like prostaglandins are closely related to signs of pain, fever, and inflammation in patients with

COVID-19[7]. Out of theoretical assumptions, studies suggested that exposure to NSAIDs might increase the risk of COVID-19; moreover, it is speculated that use of NSAIDs in COVID-19 patients may worsen the disease and increase the odds of ICU admission and death[8-11]. By contrast, other articles reported that prior exposure to NSAID does not significantly increase the risk of COVID-19 in general and is even associated with better outcomes (e.g., admission and death) in hospitalized COVID-19 patients, e.g., aspirin[12-14]. In light of the ibuprofen–COVID-19 debate and the rapidly unfolding situation of the current pandemic, this study aimed to 1) assess the prevalence use of NSAIDs in the general COVID-19 population, 2) systematically investigate the associations of NSAID use with the risk of developing COVID-19 and related outcomes, and 3) assess the safety (particularly vascular complications) of NSAIDs in patients with COVID-19.

METHODS

This study was performed in accordance with PRISMA 2020 guidelines[15] (**Table S1 in Supplemental Materials**) and has been registered on PROSPERO (International prospective register of systematic reviews) (registration number-CRD42019132063).

Literature search

Two independent researchers (Liu Xiao and Shanshan Huang) searched the PubMed,

Cochrane Library, Web of Science, EMBASE, and MedRxiv (<https://www.medrxiv.org/>) databases from December 2019 to January 2021 for relevant studies without any language restrictions. We performed the search using the following keywords: “Nonsteroidal anti-inflammatory drug” OR “NSAID” AND “2019-novel coronavirus” OR “SARS-CoV-2” OR “COVID-19” OR “2019-nCoV”. Besides, references of related studies were also reviewed to discover more potentially relevant studies. Discrepancy was discussed by two researchers through online meeting until census were reached.

Study selection/inclusion and exclusion criteria

All included studies should meet the following criteria: 1) recorded the use of NSAIDs prior or during the COVID-19 panic of general population. 2) evaluated the association between the use of NSAID and risk of developing COVID-19 and associated outcomes, such as hospitalization, severity and death in COVID-19 patients. Exclusion criteria were: 1) Reports focused on specific population, such as orthopedic and rheumatologic diseases were excluded. 2) Case reports, letters, reviews and expert opinions.

Data extraction and quality assessment

Two investigators (Xiao Liu and Shanshan Huang) independently extracted following information: name of first author's name, publication year, country, study design, sample size, mean or median age, sex, measure of exposure to NASIDs. Methods of

astern COVID-19. In present study, the intensive care unit (ICU) admission was also considered as severe COVID-19 event. The quality and risk of bias of included studies reporting use of NSAIDs and associated outcomes (e.g., risk of COVID-19, severe COVID-19, and death) was assessed by the Joanna Briggs Institute (JBI) critical appraisal check-list and Newcastle–Ottawa quality scale (NOS), respectively[16, 17]. [18]We regarded studies with an NOS of ≥ 6 stars as medium to high-quality studies; otherwise, are considered low-quality.

Outcomes

We firstly assessed the incidence of use of NASIDs in COVID-19 patients. Then the association between NASIDs and the risk of developing COVID-19 infection and associated outcomes (e.g., mechanical ventilation, hospitalization, severe COVID-19 infection, and mortality) was assessed. Finally, we focused on the safety of NASIDs use in COVID-19, particular vascular complications, such as bleeding, myocardial infraction, and stroke.

Statistical analysis

Meta-analysis was performed using international STATA15.0 (StataCorp, College Station, Texas) and RevMan5.3 (Review Manager [RevMan], version5.3, Cochrane Collaboration) software. The OR and 95% confidence intervals (95% CIs) were taken to evaluate the merged results. Risk ratio and hazard ratio from other studies were

regarded as OR. If not available, ORs could be obtained through calculating events and total numbers of patients in two groups. If both unadjusted and adjusted RRs existed in one study, we extracted both and pooled the unadjusted and adjusted, respectively. If multi-adjusted ORs were reported, we used the most completely adjusted one. The calculation and aggregation of natural logarithm of the OR (log [OR]) and its standard error (SElog [OR]) were conducted by Revman 5.3. As for evaluation of heterogeneity, Cochran's chi-square test and I^2 statistic was used. The random effects model were used to pooled the results. We also performed a subgroup analysis of types of NSAIDs which based on studies adjusted for confounding. The evaluation of publication bias was conducted by Egger's test and Begg's funnel plot. $p < 0.05$ represent there is statistical significance. Sensitivity analysis was conducted by omitting one study each.

RESULTS

Study selection

After searching the PubMed, Cochrane Library, EMBASE, and MedRxiv databases, we obtained 573 potentially relevant articles. Of these, 63 were duplicates. In addition, 447 studies were excluded after examining their titles and abstracts. Of the remaining 53 articles, 28 were excluded after a detailed review of the full text for the following reasons : 1) 8 reports assessed other respiratory infections; 2) 7 were letters, reviews,

or case reports; 3) 6 studies assessed suspected COVID-19 cases instead of confirmed disease; 4) 4 articles were based on other diseases (e.g., rheumatologic diseases, cancers, and coronary artery diseases); 5) 3 reports were based on duplicated populations. Finally, 25 publications (23 cohorts) [11-13, 19-40] were included in the present analysis (**Figure 1**).

Study characteristics and quality

The basic characteristics of the included studies are shown in Table 1. All the included patients were general COVID-19 cases. The mean age ranged from 64 to 67 years. The doses of NSAIDs were not reported in almost all studies, except one [38] in which 81 mg aspirin was administered. The diagnosis of COVID-19 was confirmed by SARS-CoV-2 PCR in most of the studies; one[40] used ICD-10, and one[13] combined clinical and SARS-CoV-2 PCR findings. The majority of studies were retrospective or prospective cohort observational trials; besides, 3 trials[22, 24, 29] were case-control studies. The assessment results showed that all articles were of medium to high quality (**Table S2-3 in Supplemental Materials**).

Use prevalence for NSAIDs in patients with COVID-19

Twenty-two articles with 106,421 patients[8-13, 19-26, 29-34, 36, 38, 39, 41-49] reported the use of NSAIDs in general COVID-19 cases. The pooled results showed a use prevalence for NSAIDs in COVID-19 patients reaching 19% (95%CI: 14%-23%),

with significant heterogeneity ($I^2=99\%$) (**Figure 2a**). Subgroup analysis showed no statistical differences in NSAID use prevalence across age, study designs, regions, and sample sizes (**Figure S1a-d in Supplemental Materials**).

The impact of NSAIDs on the risk of COVID-19

Five studies[8, 9, 22, 42, 45] with 17,239 cases among 343,286 individuals reported the effect of NSAID use on the risk of COVID-19 infection. The pooled analysis of raw data showed that use of NSAIDs did not increase the risk of COVID-19 (crude OR=0.93, 95%CI: 0.78–1.12; $I^2=83\%$) (**Figure 3a**). Three studies[8, 22, 42] evaluated the association between NSAIDs and COVID-19 infection by multivariate analysis. Consistently, there was no significant association between NSAID use and COVID-19 risk (adjusted OR=0.93, 95%CI: 0.82–1.06; $I^2=34\%$) (**Figure 3b**).

The impact of NSAID use on hospitalization in patients with COVID-19

There were 9 publications[11, 21, 22, 26, 28, 31, 35, 36, 50] with 10,955 cases/30,921 COVID-19 patients included in the analysis of NSAIDs and hospitalization. The pooled results of the unadjusted analysis showed that use of NSAIDs did not significantly elevate the risk of hospital admission (crude OR=1.05, 95%CI: 0.63–1.73; $I^2=97\%$) (**Figure 4a**). Three studies further reported the adjusted results, with a summary OR of 1.06 (95%CI: 0.76–1.48; $I^2=81\%$) (**Figure 4b**). Subgroup analysis showed all types of NSAIDs did not significantly increase the risk of severe COVID-19 after adjustment (ibuprofen, OR=0.82, 95%CI: 0.54–1.23; naproxen,

OR=0.66, 95%CI: 0.50–0.87) (**Figure S2 in Supplemental Materials**).

The impact of NSAID use on length of hospitalization in patients with COVID-19

There were 3 publications that reported the hospitalization length based on NSAID use (**Table 2**). We did not pool the results due to sufficient data. Jeong et al.[51] reported a median length of hospitalization of 12 days among NSAID users versus 13 days among non-users in COVID-19 patients. Another retrospective cohort including 412 American COVID-19 patients reported that there was no significant difference in the length of hospital stay between aspirin use and no-aspirin use[12]. A prospective cohort study that included 503 patients in Asia also showed that acute or chronic use of NSAID did not increase the length of hospital stay compared to non-NSAID users[11] ($p=0.63$). Collectively, current evidence showed NSAIDs did not increase the length of hospitalization in patients with COVID-19.

The impact of NSAID use on mechanical ventilation in patients with COVID-19

There were 6 studies[11, 12, 21, 27, 28, 36] with 459 cases/11,857 patients using mechanical ventilation. Both the pooled results of crude (crude OR=1.34, 95%CI: 0.60–3.02; $I^2=79\%$) and adjusted analysis showed no significant risk of mechanical ventilation with the use of NSAIDs in COVID-19 cases (adjusted OR=0.71; 95%CI: 0.47–1.06; $I^2=38\%$) (**Figure 4c-d**). Subgroup analysis showed all types of NASIDs did not significantly increase the risk of severe COVID-19 after adjustment (aspirin, OR=0.56, 95%CI: 0.47–1.06; ibuprofen, OR=0.75, 95%CI: 0.22–2.50; naproxen,

OR=0.36, 95%CI: 0.03–3.96) (**Figure S3 in Supplemental Materials**).

The impact of NSAID use on severe COVID-19 infection

Twelve articles involving 6,284 severe COVID-19 cases among 69,942 patients[8-12, 20-22, 27-29, 36, 39, 43-45, 49] reported the association between NSAID use and COVID-19 severity. As shown in **Figure 5a**, treatment with NASIDs was not significantly associated with the likelihood of severity in COVID-19 (crude OR=1.01, 95%CI: 0.73–1.24; $I^2=85\%$). Furthermore, pooled OR in multivariate analysis[8, 9, 12] showed significantly reduced risk of severe COVID-19 infection (adjusted OR=0.79, 95%CI: 0.71–0.89; $I^2=0\%$) (**Figure 5b**). Subgroup analysis showed all types of NASIDs did not significantly increase the risk of severe COVID-19 after adjustment (aspirin, OR=0.57, 95%CI: 0.38–0.86; ibuprofen, OR=0.98, 95%CI: 0.59–1.65; naproxen, OR=0.79, 95%CI: 0.52–1.20) (**Figure S4 in Supplemental Materials**).

The impact of NSAID use on all-cause death in patients with COVID-19

We included fifteen studies[11-13, 19, 21, 25, 27, 28, 36, 52] with 2,966 cases among 35,595 patients in the analysis of death and NSAID use in COVID-19. We observed a decreased but non-significant risk of death after NSAID use and in COVID-19 patients (crude OR=0.73, 95%CI: 0.53–1.02; $I^2=80\%$) (**Figure 5c**).

Notably, the pooled results of adjusted analysis showed that use of NSAIDs significantly decreased the risk of death in COVID-19 (adjusted OR=0.68, 95%CI: 0.52–0.89; $I^2=85\%$) (Figure 5d). Subgroup analysis showed all types of NASIDs did not significantly increase the risk of COVID-19 death after adjustment (aspirin, OR=0.41, 95%CI: 0.22–2.50; ibuprofen, OR=0.83, 95%CI: 0.69-0.99; naproxen, OR=0.92, 95%CI: 0.72–1.17) (**Figure S5 in Supplemental Materials**).

Safety of NSAID use in patients with COVID-19

The cardiovascular adverse effects of NSAIDs, such as major bleeding, heart failure, and major coronary events, are well established in the general population[53]. Therefore, we also focused on the potentially harmful effect of NSAIDs on vascular complications in COVID-19. Two propensity score matched studies reported NSAID-related safety outcomes (myocardial infarction, stroke and major bleeding)[27, 38]. The pooled results showed prescription of NSAIDs significantly increased the risk of stroke (PS matched OR=2.06, 95%CI: 1.04–5.2; $p=0.16$; $I^2=0\%$) (**Figure 6a**), but not significantly increased myocardial infraction (propensity score matched OR=1.48, 95%CI: 0.25–8.92; $I^2=0\%$) and overt thrombosis (OR=0.76, 95%CI: 0.34–1.70; $I^2=28\%$)(**Figure 6b-c**). Moreover, Chow et al.[12] found no significant difference (6.1% aspirin vs. 7.6% non-aspirin, $p=0.61$) in major bleeding between groups in the crude analysis.

Publication bias and sensitive analysis

No publication bias for susceptibility to COVID-19 was detected by the funnel plot or the Egger's test ($p>0.1$), although these tests are not recommended for outcomes for which few studies are included ($N<10$) (**Figure S6 in Supplemental Materials**).

DISCUSSION

At present, no consensual guidelines are available regarding NSAIDs use in COVID-19, reflecting a paucity of data in this regard. To the best of our knowledge, this study is the first meta-analysis that comprehensively assessed the incidence of NSAID use and associated outcomes in the general COVID-19 population. Our results showed a prevalence of NSAID use reaching 17% among the general population with COVID-19, which suggested the use of NSAIDs in patients with COVID-19 is not uncommon. Furthermore, based on current evidence, we found exposure to NSAIDs, including aspirin, ibuprofen and naproxen, was not associated with increased risk of developing COVID-19 or worse outcomes in patients with COVID-19. Notably, a significantly increased risk of thrombotic stroke was found in patients with COVID-19 administered NSAIDs ($OR=2.32$, $p<0.04$).

There is sound evidence that SARS-CoV-2 spike glycoprotein directly binds to the host cell's ACE2 receptor, which is highly expressed in human lung tissue, gastrointestinal tract, and arterial smooth muscle cells *in vivo*[54]. Indeed, the ACE receptor in humans

plays an important role in the pathophysiology of SARS-CoV-2 infection[55, 56]. Several drugs with the potential of increasing ACE2 expression have provoked great concern for potentially contributing to the spread of COVID-19 in the population, including ACEI/ARB[57] and NSAIDs[4]. However, as suggested by some researchers, there is a long way from bench to bedside. The evidence derived from mechanistic or theoretical pharmacology should be cautiously interpreted when drawing conclusions[58]. A number of examples can be found in the literature where evidence from mechanistic studies does not always corroborate data from clinical trials. For example, studies have shown that co-administration of ibuprofen and aspirin can counteract the antiplatelet effectiveness of aspirin as detected by thromboxane levels[59]. This hypothesis, however, was refuted in a large randomized controlled trial[60]. In a previously report, we demonstrated that ACEI/ARB is not associated with increased risk of COVID-19 infection and worse outcomes in the general population or hypertensive patients[61]. Similarly, regarding NSAIDs, a potential risk increase in COVID-19 with the use of NSAIDs was not found. There are several possible explanations for these findings. Firstly, although animal studies showed that ACE2 receptor expression is significantly increased by ibuprofen[62], a recent report found two commonly used NSAIDs, including ibuprofen and meloxicam, have no effect on ACE2 expression, viral entry, and viral replication in a mouse model of SARS-CoV-2 infection[63]. Furthermore, no human studies have assessed the effect of ibuprofen on ACE2 expression, particular in the lung tissue. Secondly, whether there is

a positive dose-response relationship between ACE2 expression and the risk of COVID-19 infection remains unknown. The most recent evidence derives from COVID-19 and inflammatory bowel disease. Higher ACE2 protein expression was shown in terminal ileum and colon in patients with inflammatory bowel disease compared with controls[64]. However, there is currently no evidence of increased risk or aggravated outcomes in patients with inflammatory bowel disease in the context of COVID-19[65]. Collectively, based on current data, both experiment and clinical, we suggest that there is no evidence of a positive association between NSAIDs and the risk of COVID-19.

Recent reports of potential harm (e.g., worsening symptoms) by NSAIDs in patients with COVID-19 have attracted widespread attention, and several medical agencies still have inconsistent opinions based on limited evidence[4]. In the present study, we also found the use of NSAIDs had a potential benefit in COVID-19. Indeed, NSAID use reduced the incidence of severe COVID-19 infection and all-cause mortality after adjustments. These results corroborated our previous study of ACEI/ARB, which also evoked great concern based on similar reasons regarding COVID-19[61]. There are several potential interpretations. Firstly, although some literature reviews and investigators recommend to avoid NSAIDs based on previous studies showing negative outcomes in ibuprofen users in the treatment of acute respiratory tract infections, these results might be affected by selection bias[66, 67]. The NSAID

groups might have higher disease severity compared with nonusers. For example, whilst Joeng et al.[27] found an increased composite outcome (in-hospital death, ICU admission, mechanical ventilation use, or sepsis) in the NSAID group, elevated event rate was not found compared with individuals administered paracetamol, a drug used for similar indications as NSAIDs[27]. Furthermore, it is thought that the pathophysiology and transmission of COVID-19 show differences in behavior even from other respiratory diseases[68]; therefore, the harmful effects of NSAIDs in individuals infected by other respiratory viruses might not be generalized to COVID-19. In contrast, a recent propensity score matched study of 7747 individuals showed that use of NSAIDs is not associated with 30-day intensive care unit admission or death in patients hospitalized with influenza[69]. Secondly, NSAIDs are well-known anti-inflammatory drugs that inhibit the cyclooxygenase (COX) isoforms COX-1 and COX-2. It is well-established that hyper-inflammatory responses underlie the pathology of severe COVID-19. Indeed, cytokine production is significantly increased in COVID-19. Recent findings demonstrated that NSAIDs decreased the production of a subset of proinflammatory cytokines, including Interleukin 6, and tumor necrosis factor alpha [70, 71], which might reduce the incidence of cytokine storm in COVID-19[70, 71].

Our results might be generalizable to a diverse population. In accordance with the above findings, several cohort studies also found no outcome worsening in

COVID-19 patients with coexisting comorbidities, including rheumatic disease[72], cancer[73], and coronary artery diseases[74]. For example, a national cohort study based on 1708 781 individuals with rheumatoid arthritis/osteoarthritis showed that the current use of NSAIDs is not associated with a reduced risk of COVID-19 related death after adjustment[72]. Furthermore, another cohort with a small sample size (N=183) in China found that pre-hospitalization use of low-dose aspirin is not associated with mortality in patients with CAD hospitalized with COVID-19 infection (OR=0.944, $p=0.89$)[74]. Collectively, these results showed treatment with NASIDs is also safe for other patient populations, and individuals taking NASIDs for secondary prevention should continue their treatment.

A previous study found NSAIDs use, compared with non-use, is associated with increased risk of ischemic stroke in patients with acute respiratory infections[75]. Consistently, we also found a significantly increased risk of stroke, but no overt thrombosis or myocardial infarction rate elevation after NSAID use in hospitalized COVID-19 patients by pooling two propensity score-matched studies. The somewhat contradictory results were interesting. A possible explanation between thrombosis and clinical findings is the examination of overt thrombosis and microthrombosis, which is usually the cause of thrombosis stroke. It is well-known that the presence of microthrombi does not correlate with overt thrombosis. Microthrombosis is better diagnosed with video-microscopes, dark-field images, and spectral images. Therefore,

further researches should use more effective tools to comprehensively elucidate the effect of aspirin or other NSAIDs on thrombosis.

It is well-known that NSAIDs increase the risk of major bleeding, e.g., upper gastrointestinal complications. Chow et al.[12] found no significant increase in major bleeding in patients administered aspirin, which might be explained by the fact that patients with COVID-19 are frequently hypercoagulable, and thrombocytopenia is uncommon in COVID-19 patients. However, considering the observational study design and limited sample size, ongoing COVID-19 clinical trials involving aspirin or NSAIDs would be helpful in providing sounder evidence on safety outcomes.

Age is an important confounding factor that might influence our results. Elderly people with comorbidities are more prone to routinely take NSAIDs[76] Although most of our data were adjusted for age, we cannot fully exclude the potential age-related bias. However, the NSAID groups were older in most of the included studies, and age-related adverse events cannot be underestimated. Furthermore, Wong et al. [40] reported that there is no association between NSAID use and COVID-19 related-death both in young and older individuals, and the estimated effect did not differ by age in all adjustment models. In general, current evidence suggested there is no interaction between age and NSAIDs in COVID-19.

Some authors suggested that different types of NSAIDs might lead to variable capabilities of suppressing the enzymatic activities of COX-1 and/or COX-2, affecting the production profile of downstream eicosanoids, resulting in a variety of effects[5, 6]. In the above subgroup analysis, we found that all types of NSAIDs (aspirin, ibuprofen, and naproxen) were safe for the primary care of all COVID-19 patients, which is consistent with our main results. However, because only a limited study categorized the types of NSAIDs, more research is needed to confirm our results.

Study strengths and limitations

The greatest strength of this study was its large sample size, and all trials were general population-based. We examined the use rate of NSAIDs in COVID-19 cases and comprehensively assessed the related outcomes, including the risk of COVID-19, hospital admission, severity, mechanical ventilation and death, as well as safety outcomes. As readily available and inexpensive drugs, these results revealed benefits for the clinical use of NSAIDs during the COVID-19 pandemic.

We recognize possible limitations as well. 1) There are intrinsic limitations associated with any observational study, which is unable to prove a causal relationship. 2) The included individuals were adult, and the effects of NSAIDs in young individuals and children should be further studied. 3) Measured and unmeasured factors, such as various underlying diseases, may have influenced the above results. For example, it is

thought that there is a great gender difference in COVID-19. However, the limited data prevented sex-specific subgroup analysis. 4) Some data, including age and specific drug doses, were incomplete in most included studies and could not be further analyzed. However, Wong et al.[40] reported that high or low ibuprofen or naproxen is not linked to increased risk of COVID-19 death in the general population, which suggests NSAID use is safe at common clinical doses. 5) Significant heterogeneity was observed across the included studies, which might result from between-study differences, including differences in exposure to NSAIDs, types of NSAIDs and analytical strategies. Finally, well-randomized controlled clinical trials are still required for further assessment of the clinical benefit or harm of NSAIDs at proper doses in the prevention and treatment of COVID-19, while also trying to avoid their known side effects.

Conclusions

The current findings support the notion that exposure to NSAIDs is not linked to an elevated likelihood of susceptibility to or exacerbation of COVID-19; in addition, administration of NSAIDs might be beneficial to COVID-19 outcomes to some extent. Thus, proper use of NSAIDs in COVID-19 is recommended, rather than absolute rejection. It is worth pointing out that this analysis was mostly based on observational studies, and ongoing trials (NCT0432563339, NCT0438276840, NCT0433462941 and NCT04344457) are expected to demonstrate the role of NSAIDs in the management of COVID-19. What's more, future investigations should not only focus

on the use of NSAIDs as a therapeutic option but also continue to examine the effects of pre-admission NSAID use on the risk of COVID-19 as well as COVID-19 outcomes and mortality in the general population.

Declarations

Ethics approval and consent to participate

Not applicable

Author contributions

P-Y and X-L were responsible for the entire project and revised the draft. H.L-Z, S.S-H, and K.B-M performed the data extraction, statistical analysis, and interpreting the data. X.L, and S.S- H drafted the first version of the manuscript. All authors participated in the interpretation of the results and prepared the final version of the manuscript.

Competing interests

All authors declare that they have no conflicts of interest.

Funding

This work was supported in part by the National Natural Science Foundation of China (P-Y, 81760050, 81760048) and the Jiangxi Provincial Natural Science Foundation for Youth Scientific Research (P-Y, 20192ACBL21037). Young Teachers' Basic Scientific Research Business Expenses Project (W.G-Z, 20ykpy72); China Postdoctoral Science Foundation (W.G-Z,2020M673016); China National

Postdoctoral Program for Innovative Talents (W.G-Z, BX20200400). Guangdong Medical Science and Technology Research Foundation (Y-J, A2021006);

Competing interests

All authors declare that they have no conflicts of interest.

Availability of supporting data

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Acknowledgments

None

Consent for publication

Not applicable

Figure legends

Figure 1. Flow chart of study selection

Figure 2. Forest plot for the prevalence use of **nonsteroidal anti-inflammatory drugs** in general COVID-19 population.

Figure 3. Forest plot for the association between nonsteroidal anti-inflammatory drugs and risk of COVID-19 infection. **A.** Crude effect size of the association between

nonsteroidal anti-inflammatory drugs and risk of COVID-19 infection. **B.** Adjusted effect size of the association between nonsteroidal anti-inflammatory drugs and risk of COVID-19 infection.

Figure 4. Forest plot for the association between nonsteroidal anti-inflammatory drugs and hospitalization, mechanical ventilation in COVID-19 patients. **A.** Crude effect size of the association between anti-inflammatory drugs and hospitalization in COVID-19 patients. **B.** Adjusted effect size of the association between anti-inflammatory drugs and mechanical ventilation in COVID-19 patients.

Figure 5. Forest plot for the association between nonsteroidal anti-inflammatory drugs and severity, death in COVID-19 patients. **A.** Crude effect size of the association between anti-inflammatory drugs and severity in COVID-19 patients. **B.** Adjusted effect size of the association between anti-inflammatory drugs and death in COVID-19 patients.

Figure 6. Forest plot for the association between nonsteroidal anti-inflammatory drugs and safety outcomes in COVID-19 patients. **A.** Stroke. **B.** Myocardial infraction. **C:** Over thrombosis

NOTE: Weights are from random-effects model

NSAIDs and risk of COVID-19

a

Crude analysis

b

Adjusted analysis

NSAIDs and risk of hospitaliztion

Crude analysais

a

Adjusted analysis

b

NSAIDs and risk of mechanical ventilation

Crude analysais

c

Adjusted analysis

d

NSAIDs and risk of severe COVID-19

a

Crude analysais

b

Adjusted analysis

NSAIDs and risk of death

c

Crude analysais

d

Adjusted analysis

NSAIDs and safety outcomes in COVID-19

Stroke

a

b

Myocardial infraction

c

Overt thrombosis

Table 1 Basic information of included studies

Study, year, country	Type of NSAIDs	Definition of exposure to NSAIDs	Dose of NSAIDs	Study design	Data source	Sample size	Mean age	Sex (female%)	Diagnosis of COVID-19	Outcomes included	Adjusted variables
Antsch, 2020, Austria	NSAIDs	Prescribed NSAIDs in the year before diagnosis of COVID-19 14 days	Not available	Retrospective Cohort	VA national Corporate Data Warehouse	585	66	27(4.6)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Risk of COVID-19 Hospitalisation ICU-admission	Age, sex, race, ACE/ARB use, HTN, temperature, chronic kidney disease, COPD, DM, vascular disease, systolic blood pressure, oxygen saturation, albumin, eGFR, FIB-4, hemoglobin, lymphocyte count, VACS Index score
Hamdani, 2020, Iran	NSAID	Prescribed NSAIDs in Electronic medical record	Not available	Retrospective Cohort	Hospitalized in Shahid Modarres Hospital	459	61	139(30.3)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Not applicable [#]
Genziano, 2020, USA	NSAIDs	Not available	Not available	Retrospective Cohort	Hospitalized at NYP/CUIMC	1,000	63	404(40.4)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Not applicable
King et al, 2020, USA	NSAIDs	Prescribed NSAIDs in the 4 months before diagnosis of COVID-19	Not available	Retrospective Cohort	National Health Service England database	2,463,707	53	1,410,922 (57.2)	ICD-10	COVID-19-related death	Age, sex, obesity, smoking, hypertension, HF, other heart disease, DM, COPD, asthma, other respiratory diseases such as cystic fibrosis, cancer, immunosuppressive conditions, current other medication use, region
Kim et al, 2020, South Korea	NSAIDs	Prescribed NSAIDs ≤7 days before diagnosis of COVID-19	Not available	Case-control	National hospitalized patients in HIRA database	5,172	44	2,883(55.7)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Risk of COVID-19	Age, sex, region of residence, comorbidities, healthcare, utilization, hydroxychloroquine, ACEI/ARB, metformin, thiazolidinedione, statins, sirolimus, mycophenolate, amiodarone, camostat, systemic steroid

ilev, 2020 , nmark	NSAIDs	Prescribed NSAIDs within 6 months prior to diagnosis of COVID-19	Not available	Retrospective Cohort	Nationwide data in Danish	9,519	49	5,509(58.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Risk of COVID-19	Univariate analysis ^{&}
ng, 2020 [®] , th Korea	NSAIDs	Prescribed NSAIDs within 7 days before cohort entry	Not available	Retrospective Cohort	National hospitalized patients in HIRA database	1,824	49	1,074(590)	SARS-COV-2 PCR-positive	Mechanical ventilation ICU admission Death Cardiovascular composite	PS matched for age, sex, health insurance type, hypertension, hyperlipidaemia, DM, asthma, COPD, malignancy, atherosclerosis, chronic renal failure, chronic liver disease, rheumatoid arthritis, osteoarthritis, gastrointestinal conditions, and ACEI/ARB, β -blockers, CCB, diuretics, nitrates
nd, 2020 , nmark	NSAIDs	Prescribed NSAIDs within 30 days before diagnosis of COVID-19 (defined as current use)	Not available	Retrospective Cohort	Danish health and administrative registries	1,120	54	655(58.5)	SARS-COV-2 PCR-positive	Hospitalisation ICU-admission Death	PS matched for age, sex, antihypertensives, antidiabetic drugs immunosuppressants, opioids, benzodiazepines, 1st gen. antipsychotics 2nd gen. antipsychotics, systemic glucocorticoids, inhaled corticosteroids asthma, COPD, cardiovascular disease ischemic stroke, chronic kidney failure, liver disease, alcohol related disorders dementia, cancer, overweight or obesity, Hemiplegia and paraplegia, osteoarthritis rheumatoid arthritis, dysmenorrhea
uyen, 2020, A	NSAIDs	Prescribed NSAIDs in Electronic medical records	Not available	Retrospective Cohort	Hospitalized in University of Chicago Medical Center	689	55	393(57.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Not applicable
ang, 2020 ,	NSAIDs	Prescribed NSAIDs 90 days	Not available	Case-control Cohort	UCLA Health System	843	49	438(52.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Age, sex, CAD, congestive HF, COPD, type 2 DM, hyperlipidemia,

A		before diagnosis of COVID-19								Risk of COVID-19 Hospitalisation Severe covid-19	HTN, obesity, and chronic renal disease
machandran 120, USA	NSAIDs	Prescribed NSAIDs in Electronic medical records	Not available	Retrospective Cohort	hospitalized in care academic medical center in Brooklyn	295	66	133(45.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Not applicable
iz-Antorán , 10, Spain	NSAIDs	Prescribed NSAIDs in Electronic medical records	Not available	Retrospective Cohort	hospitalized in 18 tertiary Spanish hospitals	506	67	182(36.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Death	Univariate analysis
ow, 2020 , A	Aspirin	Administration aspirin within 24 hours to 7 days before hospital admission	Not available	Retrospective Cohort	Hospitalized COVID-19 patients in CRUSH COVID study	412	60	168(40.8)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Mechanical ventilation ICU-admission In-hospital mortality	Age, BMI, ethnicity, HTN, DM, CAD, Beta Blocker, Renal Disease
oi, 2020 , rea	Ibuprofen	Prescribed NSAIDs in medical records	Not available	Retrospective Cohort	hospitalized Armed Forces Daegu Hospital	293	29	79(27.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use	Not applicable
nce, 2020, i	NSAIDs	Prescribed NSAIDs prior to admission	Not available	Retrospective Cohort	hospitalized in COVID-19 in Older People study	1,222	61	532(43.5)	Clinical or laboratory confirmed diagnosis of COVID-19	In-hospital mortality	Age group, sex, smoking status, CRP levels, diabetes, hypertension, CAD, reduced renal function
am, 2020, A	NSAIDs	Prescribed NSAIDs in Electronic medical record	Not available	Retrospective Cohort	hospitalized in Beaumont Health's eight hospitals	1,305	61.0	603(46.2)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Death	Age greater than 60 years, Comorbidities were computed into the Charlson Comorbidity Index ACEI/ARB
ai, 2020 , veland	Aspirin	Prescribed aspirin new or ongoing administration during admission	81 mg	Retrospective Cohort	Hospitalized Cleveland Clinic patients	1,994	60	1,018(51)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Mortality Safety outcomes	Propensity matched for age, platelets, gender, race, ethnicity, smoking, , oppressors, COPD, emphysema, asthma, diabetes, hypertension, CAD, HF, cancer, ongoing immunosuppressive treatment

budhi, 2020, A	NSAID	Prescribed NSAIDs in medical record	Not available	Retrospective Cohort	Massachusetts General Brigham Healthcare database	1,144	>60	515(45.0)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use ICU-admission Death	Univariate analysis
u Esba, 20, Riyadh	NSAIDs	Prescribed NSAIDs for 30-days in a 6-month before admission or patient self-reported chronic use. or NSAIDs use during admission	Not available	Prospective Cohort	King Abdulaziz Medical City and King Abdullah Specialist Children's Hospital	503	50	215(42.7)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Hospitalisation Mechanical ventilation Severe COVID-19 30-day mortality	Age, sex, comorbidities: hypertension, DM, dyslipidemia, asthma or COPD, cardiovascular disease, renal or liver impairment, and malignancy
stro,2020 , A	Ibuprofen	At least one prescription or medication order of NSAIDs in the 1 year to 30 days before COVID-19 admission	Not available	Retrospective Cohort	Hospitalized in 2 academic medical centers and 4 community affiliate hospitals	7,360	>60	3,495(47.5)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use mechanical ventilation ICU death	Age at admission, gender, race, ethnicity, Charlson comorbidity index and the presence of a prior diagnosis in the health system
Keigue,2020 Notland	NSAIDs	Prescribed NSAIDs in a 240-day before diagnosis of COVID-19	Not available	Case-control	REACT-SCOT study	2,378	NA	NA	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Severe covid-19	Proton pump inhibitors, antihistamines, antipsychotic drugs, and opioid analgesics
borne,2020, A	Aspirin	Prescribed aspirin up to 30 days before diagnosis of COVID-19	Not available	Retrospective Cohort	VA national Corporate Data Warehouse	26,346	58	2,859(10.9)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use 30-day mortality	Age, gender, and CAN* mortality score
izlish,2020, SA	Aspirin	In-hospital aspirin use	Not available	Retrospective Cohort	Yale New Haven Health System	2,785	>60	1,389(49.9)	SARS-COV-2 PCR-positive	In-hospital death	Propensity matched for age, BMI, DDmax, admission RI score, male sex, and African-American race

ii,2020 , veland	NSAID	Prescribed NSAIDs in Electronic medical record	Not available	Retrospective Cohort	Inpatient or outpatients in Cleveland Clinic	4,536	NA	2,426(53.5)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use Hospitalisation	Univariate analysis
ott, 2020 , ael	Ibuprofen	Use Ibuprofen within a week before diagnosis of COVID-19	Not available	Retrospective Cohort	Shamir Medical Centre	403	45	220(54.6)	SARS-COV-2 PCR-positive	Incidence of NSAIDs use mechanical ventilation Severe COVID-19 Death	Univariate analysis

abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans ; HIRA: Korean Health Insurance Review and Assessment Service; NYP/CUIMC: New York-Presbyterian/Columbia University Irving Medical Center; CRUSH COVID: multicenter Collaborative Research to Understand the Sequelae of Harm in COVID; REACT-SC: Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland COPD: chronic obstructive pulmonary disease; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; BMI: body mass index; CKD: Chronic kidney disease; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure

- The CAN score is a tool that assesses patients’ risk of morbidity and mortality using a wide array of data available in the EHR, including socio-demographics, clinical diagnoses, vital signs, medications, lab values, and health care utilization data. DOI:0.2106/JBJS.OA.19.00061
- the outcome of death was not included because of cross-sectional design
- the outcome of ICU-admission and death was not included because of duplicated population (Lund,2020, Danish)
- the use of NSAIDs use was not included because of duplicated population (Jeong,2020, Koean)

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.01.21256428>; this version posted May 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 2. Studies reported the relationship between use of NSAIDs and length of hospitalized days in patients with COVID-19

References (first author, year, country/region)	Study participants	Study design	Sample size	Length of hospitalization		
				Values (Median (IQR), days)		
				Group1	Group2	P
				NSAID users	Non-users	
Jeong,2020, South Korea	National hospitalized COVID-19 patients in HIRA database	Retrospective Cohort	1,824	12	13	Na
Chow,2020, USA	Hospitalized COVID-19 patients in CRUSH COVID study	Retrospective Cohort	412	No Aspirin 8 (3-19)	Aspirin 9 (5-17)	0.91
Abu Esba,2020, Riyadh	National COVID-19 hospitalized patients in Health Affairs	Prospective Cohort	503	NSAID users 7	Non-users 8	0.63

CRUSH COVID: multicenter Collaborative Research to Understand the Sequelae of Harm in COVID; COVID-19: Corona Virus Disease 2019; HIRA: Korean Health Insurance Review & Assessment Service;